





Baylor College of Medicine

Epidemiology and Clinical Impact of West Nile in Texas

Kristy Murray, DVM, PhD Professor and Vice-Chair for Research, Dept. of Pediatrics, Section of Tropical Medicine Assistant Dean, National School of Tropical Medicine Baylor College of Medicine Director, Texas Children's Hospital Center for Human Immunobiology Twitter: @drkristymurray

Emerging Arboviruses in Texas:

•Dengue

-First recognized outbreak of dengue-like illness in 1895-1896: more than 16,000 cases in Austin area*

-1922: more than 500,000 cases ("Galveston outbreak")*

St. Louis encephalitis virus

-First identified in 1933, first recognized outbreak in Texas in 1964

West Nile virus

-Introduced to US in 1999 and Texas in 2002

Chikungunya virus

-1st locally acquired case reported 2016

•Zika virus

-1st locally acquired case reported 2016

*Beaumier et al. Current Tropical Medicine Reports, 2014



West Nile Virus

Natural transmission → mosquito vector
 Houston: Culex quinquefasciatus
 Birds are reservoir host

•Newly discovered means of transmission with WNV in humans (2002)

- Transplant
- Transfusion
- Transplacental
- Breastfeeding
- Laboratory acquired
- Sexual?





West Nile Virus Clinical Features in Humans

- Incubation 2 to 15 days
- 80% infected persons asymptomatic
- 20% infected persons flu-like symptoms
- •< 1% (1 out of 150) "neuroinvasive disease"</p>
 - •WNM: Meningitis
 - •WNE: Encephalitis or meningoencephalitis
 - Acute flaccid paralysis
 - •10 % case fatality ratio for those with severe disease



West Nile Virus

Clinical Cases by Year, 1999-2016



Pediatrics

Montgomery and Murray, Expert Rev. Anti Infect. Ther., 2015.

Baylor College of

Medicine

Texas Children's

Hospital

Decade of WNV Transmission in Texas



Pediatrics

Nolan et al. Emerging Infectious Diseases, 2013

Texas Children's Hospital® or

College of

Medicine

Epidemic Curve of the 2012 West Nile Virus Outbreak in Texas: Number of Reported Cases by Date of Onset



Pediatrics

Murray et al., Emerging Infect Diseases, Nov. 2013

Hospital®

WNV Incidence per 100,000 population in 2012



Baylor College of Medicine

Houston 2014 WNV Outbreak



Martinez et al., in press, *Emerging Infectious Diseases* Pediatrics



2018 Activity as of mid-September



Study Methods

- •Study initiated in 2002 following introduction to Houston
- Cases of WNV identified through local surveillance
- Medical chart abstractions completed on all cases (n=302)
- •Cases invited to enroll in 10 year prospective, longitudinal cohort study, 267 cases currently enrolled
 - -Interviews and blood draws q. 6 mos
 - -Subjective symptoms
 - -Objective measurements: CES-D, Barthel Index, MMSE
 - -Other studies using the cohort: risk factors for encephalitis and death, clinical predictors for death, genetic susceptibility, immune functioning



Sequelae following Infection

•1 year:	60.1%
•2 years:	46.4%
•3 years:	40.6%
•4 years:	38.9%
•5 years:	41.9%

Most commonly reported sequelae: depression/personality change, weakness, fatigue, difficulty walking, blurred vision, paralysis, memory loss, confusion, headaches, tremors

•Depression: 31% new onset depression; 75% have CES-D scores indicative of clinical depression. Can continue up to 8 yrs (Murray et al, EID 2007 and Nolan et al, J Clin Psych 2012)



Kaplan-Meier Survival Curve: Percentage of Study Participants Continuing to Report West-Nile Virus-related Symptoms by Days Post-Infection based on Initial Diagnosis



	All WNV participants n=139 (%)	Neuroinvasive WNV n=67 (%)	Mild WNV n=44 (%)	Asymptomatic WNV n=28 (%)
CKD Prevalence				
CKD, All Stages	55 (40)	32 (48)	12 (27)	11 (39)
CKD Stages 3-5	13 (10)	9 (13)	3 (7)	1 (4)
CKD Stage 1-2	42 (30)	23 (34)	9 (20)	10 (36)
CKD Indicators				
Proteinuria	36(26)	21(31)	9(20)	6(21)
Hematuria	32(23)	18(27)	7(16)	7(24)
Anemia	80(60)	40(60)	23(58)	17(63)





Pediatrics

Baylor College of Medicine



West Nile Persistence

Persistent symptoms, persistent IgM, abnormal cytokine response, progressive kidney disease
Persistent infection of kidneys with shedding of viral RNA

•What about CNS persistence?



Long-Term Neurological Outcomes in West Nile Virus–Infected Patients: An Observational Study

Jill E. Weatherhead, Vicki E. Miller, Melissa N. Garcia, Rodrigo Hasbun, Lucrecia Salazar, Mazen M. Dimachkie, and Kristy O. Murray*

Baylor College of Medicine, Department of Pediatrics, Houston, Texas; The University of Texas Health Science Center at Houston, Houston, Texas; The University of Kansas Medical Center, Kansas City, Kansas

- •86% of encephalitis cases, 25% of meningitis, and 20% fever cases had abnormal neurological exams after acute infection
- Anomalies: abnormal motor strength, vibratory sensory loss, tandem gait and balance abnormalities, hearing loss, and postural or intention/action tremors
- •63% of encephalitis cases had impaired tandem gait, suggesting vestibularcerebellar and/or dorsal column dysfunction
- •At the time of the second assessment 7 years later, 57% of WNF, 33% of WNM, and 36% of WNE had developed new neurological complications.







•Cortical Thinning:

 posterior cingulate cortex, superior frontal cortex, medial-orbito frontal region, anterior cingulate cortex, inferior frontal cortex, cuneus and para hippocampal region, middle and inferior temporal cortex, supramarginal region, inferior frontal region and insular cortex

Regional atrophy



Baylor College of Medicine

Use of Testing for West Nile Virus and Other Arboviruses

Jakapat Vanichanan, Lucrecia Salazar, Susan H. Wootton, Elizabeth Aguilera, Melissa N. Garcia, Kristy O. Murray, Rodrigo Hasbun

•751 patients in Houston area diagnosed with meningitis or encephalitis, 2005-2010

- -281 (37%) were tested for WNV; only 25% of children tested
- -220/470 (47%) not tested for WNV had onset June-Oct

-518 had an unknown etiology (69%)

•Similar study ongoing at TCH: 1,699 meningitis/encephalitis cases diagnosed 2009-2014; 1,192 unknown etiology (70%); only 10% tested for WNV

Vanichanan et al. 2016, Emerging Infectious Diseases



Risk of Arboviruses in Houston: the Perfect Storm

- Proximity to endemic areas
- •Vast shipping; both air and ship travel entry points; NAFTA
- High proportion of its ~6 million residents who routinely travel to and from endemic areas
- Dense urban population
- •Abundance of Aedes sp.
- Mild winters and year-round survival of mosquitoes
- •Passive surveillance, lack of diagnostic testing available





What's next?



Zika Virus: an arbovirus and a flavivirus

FLAVIVIRUSES (ss +RNA)

- Dengue Virus
- Yellow Fever Virus
- Japanese Encephalitis Virus
- West Nile Virus
- St. Louis Encephalitis Virus
- Zika Virus



TRANSMITTED BY AEDES MOSQUITOES

• Dengue, Yellow Fever, but NOT WNV SEXUAL TRANSMISSION

Image source: Swiss Institute of Bioinformatics. Hepacivirus. http://viralzone.expasy.org/viralzone/all_by_species/37.html. Accessed February 3, 2015.





Challenges and Needs

•Best approach to combat Zika?

- -Mosquito bite prevention (Integrated Mosquito Control Management)
- -Educate on sexual transmission risk
- -Surveillance strategies
- -No treatment available.....need a vaccine!!!
- •Diagnostic tests to detect exposure

 Research to better understand risks for microcephaly, virus shedding/infectivity, clinical outcomes



Baylor College of Medicine

Dengue Virus

•Flavivirus

Four serotypes

DEN-1, DEN-2, DEN-3, DEN-4

Lifelong immunity

Complicated illness with secondary infection of different serotype

Three classifications of disease

- Dengue Fever (DF)
- Dengue Hemorrhagic Fever (DHF)
- Dengue Shock Syndrome (DSS)

Image: www.stanford.edu/.../virus/flavi/2000/dengue.htm



opyright © 1995 Leonard E. Munstermann



Epidemiology



48 WHO 2008. All rights reveryed

Communicable Diseases (CDS) World Health Organization



Epidemic Curve of Dengue IgM Positive Cases

Month and Year of Symptom Onset

= History of travel to Mexico; X = Fatal Case

Peulaulus

Hospital®

Chikungunya

•Vector: *Aedes* species mosquitoes

•"that which bends up"

-Fever, headache, fatigue, rash, nausea, vomiting, muscle pain, severe joint pain

-Fatality rare







Pan American Health Organization - World Health Organization (VHO) 2015. All rights reserved. This map is intended for general representation of geography and to be used as an exploration tool. Not for alteration, reproduction, publishing or distribution outside of PAHO-VHO and member states, without permission. The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of PAHO-VHO concerning the legal status of any country, territory, city or ense or of its authorities. or concerning the initiation of its forming on the initiation. **Introduced Western Hemisphere in 2013**

By 2015: 44 countries/territories reporting autochthonous cases

> 1.25 million cases reported in Western Hemisphere



Baylor College of Medicine

http://www.paho.org/chikungunya Map production: PAHO-WHO AD\CHA\IR\ARO

PAHO/WHO. Number of reported cases of Chikungunya Fever in the Americas



Murine Typhus Cases in Texas, 2003-2013



Geographic Distribution







Prevention of Emerging Vector-borne Diseases

•Surveillance, surveillance, surveillance

- -Humans (active + "enhanced" passive), sentinel species, mosquitoes
- -Multidisciplinary "One Health" approach is critical
- Public education
- •Prevention of bites
- Vaccine, diagnostic, and therapeutic developmentDid I mention surveillance?



Barriers to Public Health Surveillance



Large capacity for timely testing, automated electronic reporting to both medical provider and public health Diagnostic tests available, provider knows what tests to order, and patient can afford testing

Acknowledgements



- BCM, NSTM, TCH: Peter Hotez, Melissa Nolan Garcia, Rodion Gorchakov, Maria Elena Bottazzi, Laila Woc-Colburn, Coreen Beaumier, David Aguilar, Tim Erickson
- UT SPH and Medical School: Tamra Meyer, Rhia Pascual, Kelly Cain, Lara Bull
- City of Houston Health Dept: Raouf Arafat, Salma Khuwaja, Cynthia Turner
- Harris Co. PHES: Umair Shah, Cindy Kilborn, Diana Martinez, Rudy Bueno, Martin Reyna
- Texas Department of State Health Services: Jim Schuermann, Eric Fonken, Dawn Hesalroad, Nicole Evert, Duke Ruktanonchai
- Gulf Coast Regional Blood Center: Dr. Susan Rossmann

This research was supported in part by grants from the NIH (1R01Al091816-01, K23Al057341, N01 Al 50027-03, U19Al089992-01),CVRI, and the Gillson Longenbaugh Foundation Text





Thanks!



